Integration of currently known determinants of statin efficacy (i.e., gene polymorphisms, P450 enzymes, efflux and uptake transporters etc.)with known and newly detected lncRNAs implicated in atherosclerosis represents a promising field of research. This evidence concerns the gene CYP2B6 and atherosclerosis.